Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Novartis divests influenza vaccine bu...
Home  »  Community News  »  Novartis divests inf...
Novartis divests influenza vaccine business to CSL for $275 million
Pharma News

Novartis, a global healthcare company, has completed the divestiture of its influenza vaccine unit to CSL Limited for USD 275 million effective July 31, 2015.

This marks the end of a series of transactions previously announced and completed, that are focusing Novartis on its three leading businesses of global scale – pharmaceuticals, generics and eye care.

Since April 2014, the influenza vaccines unit results have been reported under discontinuing operations in the Novartis consolidated financial statements.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. The company offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals.

Leave a reply

You must be logged in to post a comment.